Literature DB >> 1730872

IL-2 induces IL-6 production in human monocytes.

T Musso1, I Espinoza-Delgado, K Pulkki, G L Gusella, D L Longo, L Varesio.   

Abstract

IL-2 is a potent activator of effector and secretory activities of human monocytes. Since monocytes are an important source of IL-6, we investigated whether IL-2 can induce IL-6 production and whether regulatory circuits can modulate this process. We found that stimulation of monocytes with IL-2 induced expression of IL-6 mRNA and bioactivity in a dose-dependent manner. Production of IL-6 in monocytes can be induced by other cytokines such as IL-1 beta. By using mAb alpha-IL-1 beta we showed that IL-2-induced IL-6 production is not mediated by the autocrine stimulation of IL-1 beta elicited by IL-2. IL-6 induction by monocytes is not a common response to activating signals because IFN-gamma did not induce IL-6 expression under conditions in which it elicits tumoricidal activity. In contrast, IFN-gamma could completely abrogate the induction of IL-6 expression by IL-1 beta but did not affect the levels of mRNA and the secretion of IL-2-elicited IL-6. We have previously reported that transforming growth factor-beta inhibits IL-6 production in response to IL-1 beta. Studies on the inhibitory activity of transforming growth factor-beta demonstrated that this cytokine differs from IFN-gamma because it inhibited both IL-1- and IL-2-induced IL-6 expression. These data demonstrate that, in human monocytes, both IL-1 and IL-2 stimulate IL-6 expression by independent mechanisms that can be dissociated by the susceptibility to the inhibitory effect of IFN-gamma. IL-6 production is also down-regulated by TGF-beta, whose inhibitory activity is stimulus-unrelated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730872

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.

Authors:  Maggie L Diller; Ragini R Kudchadkar; Keith A Delman; David H Lawson; Mandy L Ford
Journal:  J Immunother       Date:  2016 Nov/Dec       Impact factor: 4.456

2.  Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent.

Authors:  C Söderberg-Nauclér; D N Streblow; K N Fish; J Allan-Yorke; P P Smith; J A Nelson
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells.

Authors:  A J Puren; G Fantuzzi; Y Gu; M S Su; C A Dinarello
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

4.  Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice.

Authors:  F Amiot; C Fitting; K J Tracey; J M Cavaillon; F Dautry
Journal:  Mol Med       Date:  1997-12       Impact factor: 6.354

5.  Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis.

Authors:  A Crilly; S Kolta; M Dougados; R D Sturrock; B Amor; H A Capell; R Madhok
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

6.  Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells.

Authors:  K Tamura; J Woo; M T Bakri; A W Thomson
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

Review 7.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

8.  Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

Authors:  M A Caligiuri; C Murray; M J Robertson; E Wang; K Cochran; C Cameron; P Schow; M E Ross; T R Klumpp; R J Soiffer
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 9.  Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.

Authors:  Uriel Halbreich
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.

Authors:  X Cao; W Zhang; S Gu; Y Yu; Q Tao; T Ye
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.